Drug Profile
PRL 002
Latest Information Update: 04 Sep 2023
Price :
$50
*
At a glance
- Originator Perle Bioscience
- Class Peptides
- Mechanism of Action Pancreatic beta cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 1 diabetes mellitus; Type 2 diabetes mellitus
Most Recent Events
- 04 Sep 2023 Discontinued - Preclinical for Type 1 diabetes mellitus in USA (Parenteral)
- 04 Sep 2023 Discontinued - Preclinical for Type 2 diabetes mellitus in USA (Parenteral)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in USA (Parenteral)